~~<i id='C2EC0957AD'><strike id='C2EC0957AD'><tt id='C2EC0957AD'><pre id='C2EC0957AD'></pre></tt></strike></i>~~

Home» leisure time» fashion

fashion

author：fashion 2025-09-30 02:50:39 Page View：588

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New lawsuit accuses health insurer Cigna of denying claims in bulk
Next article： Bright Health sells Medicare Advantage business to Molina

focus

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

The battle over 'scope creep' and who gets to be called 'doctor'

StephanieW.EdmondsandGinnyL.Ryanarebothdoctors.Edmonds,aregisterednurse,hasaPh.D.;Ryanisatraditional

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

WSS

fashion

fashion

explore

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban